Fairfield, Bush & Co. Vertex Pharmaceuticals Inc Transaction History
Fairfield, Bush & Co.
- $169 Billion
- Q1 2024
A detailed history of Fairfield, Bush & Co. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Fairfield, Bush & Co. holds 2,066 shares of VRTX stock, worth $980,461. This represents 0.51% of its overall portfolio holdings.
Number of Shares
2,066
Previous 1,396
47.99%
Holding current value
$980,461
Previous $568 Million
52.04%
% of portfolio
0.51%
Previous 0.33%
Shares
4 transactions
Others Institutions Holding VRTX
# of Institutions
1,625Shares Held
222MCall Options Held
1.35MPut Options Held
1.49M-
Capital World Investors Los Angeles, CA25.6MShares$12.1 Billion1.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA22.7MShares$10.8 Billion0.19% of portfolio
-
Black Rock Inc. New York, NY22MShares$10.4 Billion0.22% of portfolio
-
State Street Corp Boston, MA12MShares$5.7 Billion0.23% of portfolio
-
Alliancebernstein L.P. New York, NY7.1MShares$3.37 Billion1.08% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $122B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...